STATES PATENT AND TRADEMARK Q APPLICATION Group Art Unit ິ 1811 Examiner: N. Minnifield ENGEL et Inventor(s): 217506 **PMS** 93 116 PH Atty. Dkt. Appln. No.: Series Code ↑ **Client Ref** (Our Deposit Account No. 03-3975) June 6, 1995 Filed: OLIGOPEPTIDE LYOPHILISATE . . . USE Title: (Our Order No. 11468 217506 April 20, 1998 Asst. Commissioner of Patents Date: Washington, D.C. 20231 Sir:

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED 1. "Small Entity" statement(s) filed Highest number Present Extra Large/Small Entity **Additional Fee** Claims ☐ previously Code ☐ herewith remaining after previously paid for amendment 2. Total Effective Claims 20 **minus 20 0 x \$22/\$11 =+0103/203 ***minus +82 102/202 3. Independent Claims 3 x \$82/\$41 =4. If amendment enters proper multiple dependent claim(s) into this application for first + \$270/\$135 = +0104/204 time (leave blank if this is a reissue application) 5. Original due Date: APRIL 22, 1998 \$110/\$55 = 115/215 6. Petition is hereby made to extend the original (1 mo) 116/216 \$400/\$200 = + 0 due date to cover the date this response is filed (2 mos) 117/217 (3 mos) \$950/\$475 = for which the requisite fee is attached 7. Enter any previous extension fee paid since above original due date and subtract **Extension Fee Attached** 8. 9. If Terminal Disclaimer attached, add Rule 20(d) official fee + \$110/\$55 =+0148/248 + \$240 =126 +0122 or if Rule 97(d) Petitionadd + \$130 = + \$790/395 = +011. After-Final Request Fee per rules 129(a) and 17(r) 146/246 12. No. of additional inventions for examination per Rule 129(b)..... x \$790/395 ea =+0149/249 13. Petition fee for TOTAL FEE ENCLOSED = \$82 14.

15.	*If the	entry in	this space is	less	than (entry 11	n nex	t space,	the	Presei	it Extra	resuit	18 "U	Γ.
			• .											

Sig:

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately

Pillsbury	Madison & Sutro LLP
Intellectu	al Property Group
By Atty:	Ann S. Hobbs, Ph.D.

1100 New York Avenue, N.W. Ninth Floor East Tower

Ann S. Hobbs, Ph.D.

Reg. No. 36,830

(202) 822-0944

Washington, D.C. 20005-3918 n.J. (294) 保いまの0000004 08458145 Fax:

(202) 861-3063

/Sec: ASH/maf

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

^{16. **}If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

^{17. ***}If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

IN THE UNITED, STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

ENGEL et al

Appln. No. 08/468,145

Group Art Unit: 1811

Filed: June 6, 1995

Examiner: N. Minnifield

Title: OLIGOPEPTIDE LYOPHILISATE, THEIR PREPARATION AND USE

April 20, 1998

AMENDMENT

Hon. Commissioner of Patents and Trademarks Washington, D C. 20231 APR 2 A 1998

Sir:

In response to the Office Action issued January 22, 1998, please enter the following amendments and consider the following remarks.

IN THE CLAIMS:

Please enter the following claims:

--20. A method for the preparation of a sterile

Cetrorelix lyophilizate, said method comprising the steps of dissolving Cetrorelix in aqueous acetic acid to form a solution,

diluting said solution with water for injection,
adding a bulking agent to the solution, and
sterile filtering, dispensing into injection vials and
lyophilizing the solution,

thereby obtaining a sterile Cetrorelix lyophilizate.

Sub